All In Biotech

Drug Trial Radar · NCT03694353

Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU

An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/Day Dose) in Adults With Phenylketonuria

Last checked: Nov 20, 2026Latest source record: Feb 17, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

37

Actual

Start

Sep 13, 2018

Primary completion

Jan 13, 2021

Study completion Jan 13, 2021

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Oct 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 open-label extension study enrolling adult patients with PKU who were previously treated with pegvaliase in Studies PAL-003 (NCT00924703) or 165-302 (NCT02468570). The study is designed to evaluate the long-term safety and efficacy of pegvaliase administered at doses \> 40 mg/day to 60 mg/day.

Conditions

  • Phenylketonuria (PKU)

Interventions

  • PegvaliaseDrug

    40-60mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0Time frame: Up to Day 741 (approximately Week 106)
  2. Change in Blood Phe ConcentrationTime frame: The Outcome Measure Data Table below uses the 'analysis visit' as defined by the mapping rule in the SAP. The last Phe measurement was mapped to 'analysis visit' week 121. The actual date of the last Phe measurement was day 836 (approximately Week 119).

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of Florida

    Gainesville, Florida

  • University of South Florida

    Tampa, Florida

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Indiana CTSI Clinical Research Center

    Indianapolis, Indiana

  • University of Kentucky Medical Center

    Lexington, Kentucky

  • Wayne State University, Center for Molecular Medicine and Genetics, Pediatrics and Pathology

    Detroit, Michigan

  • University of Missouri Health Care

    Columbia, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Morristown Medical Center

    Morristown, New Jersey

  • University of Oklahoma Health Science Center

    Oklahoma City, Oklahoma

  • Oregon Health and Science University

    Portland, Oregon

  • St. Christopher's Hospital for Children

    Philadelphia, Pennsylvania

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Health Science Center at Houston

    Houston, Texas

  • Medical College of Milwaukee

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.